Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.vigilneuro.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $8.00 | Buy → Hold | Stifel |
| 12/4/2024 | Outperform | William Blair | |
| 12/19/2023 | $13.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 10/18/2023 | $23.00 | Mkt Outperform | JMP Securities |
| 3/31/2023 | $15.00 | Buy | Mizuho |
| 9/16/2022 | $19.00 | Outperform | Wedbush |
| 8/29/2022 | $24.00 | Buy | H.C. Wainwright |
| 2/1/2022 | $17.00 | Equal-Weight | Morgan Stanley |
| 2/1/2022 | $23.00 | Buy | Guggenheim |
| 2/1/2022 | $24.00 | Buy | Stifel |
Stifel downgraded Vigil Neuroscience from Buy to Hold and set a new price target of $8.00
William Blair initiated coverage of Vigil Neuroscience with a rating of Outperform
Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously
JMP Securities initiated coverage of Vigil Neuroscience with a rating of Mkt Outperform and set a new price target of $23.00
Mizuho initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $15.00
Wedbush initiated coverage of Vigil Neuroscience with a rating of Outperform and set a new price target of $19.00
H.C. Wainwright initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $24.00
Morgan Stanley initiated coverage of Vigil Neuroscience with a rating of Equal-Weight and set a new price target of $17.00
Guggenheim initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $23.00
Stifel initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $24.00